RxDoctor Payments Data

Eric Fontenot, MD

Internal Medicine · Lafayette, LANPI 1437228657

Payments from drug & device makers

$1,015in general payments, 2019–2025

Across 63 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$196
  • AbbVie$114
  • Amgen$106
  • AstraZeneca$104
  • Amarin Pharma, Inc.$98
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$71
  • plus $325 from 14 others

What the payments were for

  • Food & beverage$1,015100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,015 in reported general payments places this provider in the 65th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$276,839
Medicare patients
300
Services billed
5,573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$35,364
XareltoRivaroxaban29$26,025
EliquisApixaban31$20,625
MounjaroTirzepatide19$19,940
TrulicityDulaglutide12$15,077
JardianceEmpagliflozin15$13,826
CreonLipase/Protease/Amylase12$13,281
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,487
SynthroidLevothyroxine Sodium66$3,866
Levothyroxine Sodium296$2,640
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$2,586
Pantoprazole Sodium97$2,507
Losartan Potassium155$2,102
Potassium Chloride36$2,005
Celecoxib71$1,827

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$17$35,36429 claims
Lilly USA, LLCMounjaro, Trulicity$196$35,01731 claims
Johnson & JohnsonXarelto$19$26,02529 claims
PfizerEliquis, Paxlovid$41$22,05551 claims
AbbVieCreon, Synthroid$114$17,14778 claims
Boehringer IngelheimJardiance$34$13,82615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →